drugset / Trial / NCT05099666
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Phase 1/2
Active not recruiting
62 enrolled
Massachusetts General Hospital
Jazz Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This research study involves the study drug lurbinectedin in combination with doxorubicin. This research has two parts. The first part is being done to determine the tolerability of lurbinectedin with doxorubicin in people with soft tissue sarcoma. The second part is a randomized study to determine which is more effective at treating leiomyosarcoma, lurbinectedin with doxorubicin or lurbinectedin alone.
Timeline
- Start
- 2022-02-04
- Primary completion
- 2026-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Lurbinectedin | Other / unclassified | — | Intravenous |